肿瘤坏死因子抑制剂对类风湿关节炎所致周围神经病变的影响：一项队列研究。
Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study.
作者信息
Wang Naizhi, Guo Yingying, Yang Lili, Fu Wenyi, Xu Yanbing, Hou Linxin, Zhao Shuai, Zhang Ning
机构信息
Department of Rheumatism, Shengjing Hospital, China Medical University, Shenyang 110004, Liaoning Province, China.
出版信息
Neural Regen Res. 2012 Apr 15;7(11):862-6. doi: 10.3969/j.issn.1673-5374.2012.11.011.
In this historical cohort study, 236 patients with primary rheumatoid arthritis were treated with the tumor necrosis factor inhibitors, etanercept or infliximab (n = 80), or by conventional methods (n = 156). Results revealed that 11 patients developed varying types of peripheral neuropathy at 1-2 years post-treatment (mean 16 months). The incidence of peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 8.8% (7/80), which was significantly higher than the conventional treatment group (2.6%; 4/156). The relative risk of developing peripheral neuropathy in the tumor necrosis factor inhibitors treatment group was 3.41 (95% confidence interval: 1.03-11.31). Comparison of the tumor necrosis factor inhibitors revealed that etanercept and infliximab had no significant difference in terms of inducing peripheral neuropathy. Experimental findings indicate that tumor necrosis factor inhibitors may increase the risk of peripheral neuropathy.
在这项历史性队列研究中，236例原发性类风湿关节炎患者接受了肿瘤坏死因子抑制剂（依那西普或英夫利昔单抗，n = 80）治疗，或采用传统方法治疗（n = 156）。结果显示，11例患者在治疗后1至2年（平均16个月）出现了不同类型的周围神经病变。肿瘤坏死因子抑制剂治疗组周围神经病变的发生率为8.8%（7/80），显著高于传统治疗组（2.6%；4/156）。肿瘤坏死因子抑制剂治疗组发生周围神经病变的相对风险为3.41（95%置信区间：1.03 - 11.31）。对肿瘤坏死因子抑制剂的比较显示，依那西普和英夫利昔单抗在诱发周围神经病变方面无显著差异。实验结果表明，肿瘤坏死因子抑制剂可能会增加周围神经病变的风险。
Zotero 插件